<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828243</url>
  </required_header>
  <id_info>
    <org_study_id>07-0156</org_study_id>
    <secondary_id>R01HL082747</secondary_id>
    <nct_id>NCT00828243</nct_id>
  </id_info>
  <brief_title>Genetic Regulation of Surfactant Deficiency</brief_title>
  <official_title>Genetic Regulation of Surfactant Deficiency in Human Newborn Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inherited deficiencies in any one of 3 genes (surfactant protein B, surfactant protein C, and
      ATP-binding cassette transporter A3) can cause neonatal respiratory distress syndrome by
      disrupting metabolism of the pulmonary surfactant. The investigators will use state of the
      art methods to link specific changes in the genetic code of each of these genes with
      disruption of discrete steps in the metabolism of the pulmonary surfactant in human newborn
      infants. These studies will lead to improved diagnostic capabilities and suggest novel
      strategies to correct surfactant deficiency in newborn infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genetic regulation of neonatal pulmonary surfactant deficiency has been suggested by studies
      of gender, genetic linkage, recurrent familial cases, targeted gene ablation in murine
      lineages, and by racial disparity in risk of neonatal respiratory distress syndrome.
      Successful fetal-neonatal pulmonary transition requires production of the pulmonary
      surfactant, a phospholipid-protein film that lines alveoli and maintains alveolar patency at
      end expiration. Our goal is to understand the genetic mechanisms that disrupt pulmonary
      surfactant metabolism and cause neonatal respiratory distress syndrome. Studies in human
      newborn infants have demonstrated that 3 genes are critical for surfactant metabolism:
      surfactant protein B (SFTPB), surfactant protein C (SFTPC), and an ATP-binding cassette
      transporter, ABCA3 (ABCA3). To understand genetic regulatory mechanisms, we will investigate
      the contribution of variation in each of these genes to risk of neonatal respiratory distress
      syndrome by testing the hypothesis that genetic variants in the SFTPB, SFTPC, and ABCA3
      disrupt pulmonary surfactant metabolism. Using high throughput automated sequencing to
      genotype, multidimensional protein identification technology to assess quantitative and
      qualitative differences in surfactant protein B and C expression, in vivo metabolic labeling
      with stable isotopically labeled precursors to estimate surfactant protein B and C and
      phospholipid metabolic rates, and cohort sizes that provide statistical power (0.8), we will
      use race-specific, severity-stratified case-control (N=480) and case comparison (N=250)
      designs to understand genetically regulated, metabolic mechanisms that cause surfactant
      deficiency by disrupting expression or altering processing of surfactant proteins B or C or
      by disrupting surfactant phospholipid composition in human newborn infants. Improved
      understanding of genetic regulation of surfactant deficiency will suggest novel diagnostic
      strategies to identify and categorize high risk infants and therapeutic strategies that
      target discrete steps in pulmonary surfactant metabolism to improve outcomes of infants with
      neonatal respiratory distress syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of specific variants or interactions among variants in SFTPB, SFTPC, and ABCA3 with neonatal respiratory distress syndrome</measure>
    <time_frame>1 week</time_frame>
    <description>Statistical association of increased risk of neonatal respiratory distress in term or near term infants with specific genomic variants in SFTPB, SFTPC, and ABCA3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of specific variants or interactions among variants in SFTPB, SFTPC, and ABCA3 with fractional synthetic rate and/or fractional catabolic rate of surfactant phospholipids, surfactant protein-B, and surfactant protein-C</measure>
    <time_frame>1 week</time_frame>
    <description>Statistical association of quantitative surfactant phospholipid metabolic characteristics with specific genomic variants in SFTPB, SFTPC, and ABCA3</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">773</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>Case-control</arm_group_label>
    <description>Infants with varying degrees of neonatal respiratory distress syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutrient</arm_group_label>
    <description>Infants up to 6 months of age with varying severity of respiratory distress receive stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based measurement of surfactant kinetics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nutrient</intervention_name>
    <description>We administer stable isotopically labeled precursors of surfactant phospholipids (palmitate and acetate) and of surfactant-associated proteins (leucine) to infants with neonatal respiratory distress syndrome. We measure with mass spectrometry incorporation of stable isotopically labeled precursors into tracheal aspirates to estimate surfactant phospholipid and protein kinetics.</description>
    <arm_group_label>Nutrient</arm_group_label>
    <other_name>Palmitate, acetate, leucine</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples and tracheal aspirate samples will be retained on each study participant.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes infants with and without neonatal respiratory distress
        syndrome (N=480) and infants with varying severity of neonatal respiratory distress
        syndrome (N=250).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants who require mechanical ventilation via endotracheal tube or tracheostomy in
             the first year of life

        Exclusion Criteria:

          -  Infants with conditions likely to cause imminent death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. S. Cole, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tomazela DM, Patterson BW, Hanson E, Spence KL, Kanion TB, Salinger DH, Vicini P, Barret H, Heins HB, Cole FS, Hamvas A, MacCoss MJ. Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics. Anal Chem. 2010 Mar 15;82(6):2561-7. doi: 10.1021/ac1001433.</citation>
    <PMID>20178338</PMID>
  </reference>
  <reference>
    <citation>Hamvas A, Nogee LM, Wegner DJ, Depass K, Christodoulou J, Bennetts B, McQuade LR, Gray PH, Deterding RR, Carroll TR, Kammesheidt A, Kasch LM, Kulkarni S, Cole FS. Inherited surfactant deficiency caused by uniparental disomy of rare mutations in the surfactant protein-B and ATP binding cassette, subfamily a, member 3 genes. J Pediatr. 2009 Dec;155(6):854-859.e1. doi: 10.1016/j.jpeds.2009.06.006. Epub 2009 Aug 3.</citation>
    <PMID>19647838</PMID>
  </reference>
  <reference>
    <citation>Hamvas A, Heins HB, Guttentag SH, Wegner DJ, Trusgnich MA, Bennet KW, Yang P, Carlson CS, An P, Cole FS. Developmental and genetic regulation of human surfactant protein B in vivo. Neonatology. 2009;95(2):117-24. doi: 10.1159/000153095. Epub 2008 Sep 6.</citation>
    <PMID>18776725</PMID>
  </reference>
  <reference>
    <citation>McBee AD, Wegner DJ, Carlson CS, Wambach JA, Yang P, Heins HB, Saugstad OD, Trusgnich MA, Watkins-Torry J, Nogee LM, Henderson H, Cole FS, Hamvas A. Recombination as a mechanism for sporadic mutation in the surfactant protein-C gene. Pediatr Pulmonol. 2008 May;43(5):443-50. doi: 10.1002/ppul.20782.</citation>
    <PMID>18383112</PMID>
  </reference>
  <reference>
    <citation>Garmany TH, Wambach JA, Heins HB, Watkins-Torry JM, Wegner DJ, Bennet K, An P, Land G, Saugstad OD, Henderson H, Nogee LM, Cole FS, Hamvas A. Population and disease-based prevalence of the common mutations associated with surfactant deficiency. Pediatr Res. 2008 Jun;63(6):645-9. doi: 10.1203/PDR.0b013e31816fdbeb.</citation>
    <PMID>18317237</PMID>
  </reference>
  <reference>
    <citation>Anadkat JS, Kuzniewicz MW, Chaudhari BP, Cole FS, Hamvas A. Increased risk for respiratory distress among white, male, late preterm and term infants. J Perinatol. 2012 Oct;32(10):780-5. doi: 10.1038/jp.2011.191. Epub 2012 Jan 5.</citation>
    <PMID>22222548</PMID>
  </reference>
  <reference>
    <citation>Agrawal A, Hamvas A, Cole FS, Wambach JA, Wegner D, Coghill C, Harrison K, Nogee LM. An intronic ABCA3 mutation that is responsible for respiratory disease. Pediatr Res. 2012 Jun;71(6):633-7. doi: 10.1038/pr.2012.21. Epub 2012 Feb 15.</citation>
    <PMID>22337229</PMID>
  </reference>
  <reference>
    <citation>Bereman MS, Tomazela DM, Heins HS, Simonato M, Cogo PE, Hamvas A, Patterson BW, Cole FS, MacCoss MJ. A method to determine the kinetics of multiple proteins in human infants with respiratory distress syndrome. Anal Bioanal Chem. 2012 Jun;403(8):2397-402. doi: 10.1007/s00216-012-5953-3. Epub 2012 Apr 14.</citation>
    <PMID>22526637</PMID>
  </reference>
  <reference>
    <citation>Wambach JA, Wegner DJ, Depass K, Heins H, Druley TE, Mitra RD, An P, Zhang Q, Nogee LM, Cole FS, Hamvas A. Single ABCA3 mutations increase risk for neonatal respiratory distress syndrome. Pediatrics. 2012 Dec;130(6):e1575-82. doi: 10.1542/peds.2012-0918. Epub 2012 Nov 19.</citation>
    <PMID>23166334</PMID>
  </reference>
  <reference>
    <citation>Wambach JA, Wegner DJ, Heins HB, Druley TE, Mitra RD, Hamvas A, Cole FS. Synonymous ABCA3 variants do not increase risk for neonatal respiratory distress syndrome. J Pediatr. 2014 Jun;164(6):1316-21.e3. doi: 10.1016/j.jpeds.2014.02.021. Epub 2014 Mar 20.</citation>
    <PMID>24657120</PMID>
  </reference>
  <reference>
    <citation>Wambach JA, Casey AM, Fishman MP, Wegner DJ, Wert SE, Cole FS, Hamvas A, Nogee LM. Genotype-phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1538-43. doi: 10.1164/rccm.201402-0342OC.</citation>
    <PMID>24871971</PMID>
  </reference>
  <reference>
    <citation>Jackson T, Wegner DJ, White FV, Hamvas A, Cole FS, Wambach JA. Respiratory failure in a term infant with cis and trans mutations in ABCA3. J Perinatol. 2015 Mar;35(3):231-2. doi: 10.1038/jp.2014.236.</citation>
    <PMID>25712598</PMID>
  </reference>
  <results_reference>
    <citation>Wambach JA, Yang P, Wegner DJ, An P, Hackett BP, Cole FS, Hamvas A. Surfactant protein-C promoter variants associated with neonatal respiratory distress syndrome reduce transcription. Pediatr Res. 2010 Sep;68(3):216-20. doi: 10.1203/00006450-201011001-00421.</citation>
    <PMID>20539253</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>F. Sessions Cole, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Pulmonary surfactants</keyword>
  <keyword>Pulmonary surfactant associated protein B</keyword>
  <keyword>Pulmonary surfactant associated protein C</keyword>
  <keyword>ATP-binding cassette protein sub member family A3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
    <mesh_term>Pulmonary Surfactant-Associated Proteins</mesh_term>
    <mesh_term>Pulmonary Surfactant-Associated Protein B</mesh_term>
    <mesh_term>Pulmonary Surfactant-Associated Protein C</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

